Navigation Links
Cellumen to Collaborate With the NCTR of the FDA to Apply Cellular Systems Biology (CSB(TM)) to Predictive Toxicology
Date:6/30/2008

PITTSBURGH, June 30 /PRNewswire/ -- Cellumen, Inc., the Cellular Systems Biology Company, announced today the initiation of a research collaboration with the National Center for Toxicology Research (NCTR), a research center of the Food and Drug Administration (FDA). Under the agreement, Cellumen will use its proprietary CellCiphr(R) toxicity risk assessment technology to profile blinded samples of known liver toxicity compounds including both failed and marketed drugs for the NCTR. The NCTR will incorporate the knowledge generated by Cellumen to develop a liver toxicity knowledge base. Cellumen will use the profiling data and compound safety data from the collaboration to further develop the diversity in the CellCiphr database and the types of cell panels, as well as to advance the classifier informatics tools.

"Failure to predict human toxicity among drug candidates early in the discovery/development process is a leading challenge for the pharmaceutical industry," stated D. Lansing Taylor, Ph.D., CEO of Cellumen. "Patients demand and deserve safe and effective drugs, while pharmaceutical companies are increasingly challenged to profitably meet that demand. Cellumen's vision is working toward the goal of replacing animal testing with a human in vitro system in order to facilitate the development of safer, more effective drugs," added Dr. Taylor.

By applying CellCiphr toxicity profiling early in the discovery and lead optimization phases, drug companies will accurately identify compounds with high human toxic liabilities. Actions can be taken to either de-prioritize high-risk compounds, or remove high-risk compounds from a lead series that ultimately would prove to be toxic. Cellumen is at the forefront of drug safety profiling services to aid in predicting drug toxicity early in the discovery/development process.

About Cellumen:

Cellumen is the leading innovator in cellular systems biology (CSB(TM)) solutions providing the most accurate predictions of drug efficacy and safety, thus reducing failure rates and cutting development costs. Cellumen's CSB solutions are driving "Discovery Toxicology" by addressing the full complexity of disease and safety. Leading global organizations such as the Mayo Clinic, Hamamatsu Photonics K.K., the EPA, NIH and top pharmaceutical companies partner with Cellumen.

About CellCiphr(R):

CellCiphr is the only cell-based assay solution combining tissue-specific cells, multiplexed functional biomarkers, advanced classifiers, and a compound reference library in order to allow drug developers to accurately identify drug candidates that have high efficacy and low toxicity. CellCiphr is capable of analyzing greater than 10 functional biomarkers per assay that are used as sentinels for analysis of mechanism of action and toxicity of new compounds applied to both rodent and human cells.


'/>"/>
SOURCE Cellumen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cellumen Establishes Collaboration in Breast Cancer Patient Stratification
2. ZyGEM and DIAGNOTEC Collaborate on Diagnostics for Detecting a Devastating Virus Attacking Salmon
3. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
4. LI-COR(R) Biosciences and Tiger Woods Learning Center Collaborate to Develop High School Curriculum in Genetics
5. ThalesNano Inc. and sanofi-aventis R&D Collaborate on Continuous Process Chemistry in Order to Dramatically Reduce Drug Realization Time
6. Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
7. Fred Hutchinson Cancer Research Center and NSB POSTECH, Inc. to Collaborate on Development of New Class of Proteomic Microarrays
8. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
9. Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
10. NIH collaborates with EPA to improve the safety testing of chemicals
11. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... CA, USA (PRWEB) , ... October 11, 2017 , ... ... to take place on 7th and 8th June 2018 in San Francisco, CA. The ... influencers as well as several distinguished CEOs, board directors and government officials from around ...
(Date:10/11/2017)... Oct. 11, 2017  VMS BioMarketing, a leading provider of ... oncology Clinical Nurse Educator (CNE) network, which will launch this ... communication among health care professionals to enhance the patient care ... staff, and other health care professionals to help women who ... ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/11/2017)... ... October 11, 2017 , ... Singh Biotechnology ... drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator of Transcription ... is able to cross the cell membrane and bind intracellular STAT3 and inhibit ...
Breaking Biology Technology:
(Date:4/24/2017)... Janice Kephart , former 9/11 ... Partners, LLP (IdSP) , today issues the following ... March 6, 2017 Executive Order: Protecting the ... be instilled with greater confidence, enabling the reactivation ... applications are suspended by until at least July ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... Annual Report on Form 10-K on Thursday April 13, 2017 with ... ... Relations section of the Company,s website at http://www.nxt-id.com  under "SEC ... . 2016 Year Highlights: Acquisition ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):